Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jun 1;15(6):665-74.
doi: 10.4161/cbt.28555. Epub 2014 Mar 20.

Melanoma immunotherapy

Martina Sanlorenzo  1 , Igor Vujic  2 , Christian Posch  2 , Akshay Dajee  3 , Adam Yen  3 , Sarasa Kim  3 , Michelle Ashworth  3 , Michael D Rosenblum  3 , Alain Algazi  3 , Simona Osella-Abate  4 , Pietro Quaglino  4 , Adil Daud  3 , Susanna Ortiz-Urda  3
Affiliations
Review

Melanoma immunotherapy

Martina Sanlorenzo et al. Cancer Biol Ther. .

Abstract

Immunotherapy is a cornerstone in the treatment of melanoma, and is intended to modulate the host immunity against the tumor. Immunotherapy can be used in an adjuvant setting, after complete surgical excision in patients with a high risk of disease relapse and as a treatment in advanced (unresectable or metastatic) stages. Development of novel therapeutic approaches and the optimization of existing therapies hold a great promise in the field of melanoma therapy research. Different clinical trials are ongoing, and immunotherapy is showing the ability to confirm durable clinical benefits in selected groups of melanoma patients. The aim of this review is to summarize different types of immunotherapy agents, as well as to discuss different strategies, complementary regimens, and possible biomarkers of response to the treatment.

Keywords: CTLA-4; PD-1; anti-PD-1; immunoprofiling; interferons; interleukins; ipilimumab.

PubMed Disclaimer

Figures

None
Figure 1. Methods in cancer immunotherapy.
None
Figure 2. Drugs FDA-approved for the treatment of melanoma with approval date.
None
Figure 3. Dendritic cell and T cell interaction.
None
Figure 4. T cell and cancer cell interaction.
See this image and copyright information in PMC

References

    1. Quaglino P, Marenco F, Osella-Abate S, Cappello N, Ortoncelli M, Salomone B, Fierro MT, Savoia P, Bernengo MG. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol. 2010;21:409–14. doi: 10.1093/annonc/mdp325. - DOI - PubMed
    1. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000;6(Suppl 1):S11–4. - PubMed
    1. Di Giacomo AM, Calabrò L, Danielli R, Fonsatti E, Bertocci E, Pesce I, Fazio C, Cutaia O, Giannarelli D, Miracco C, et al. Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. Cancer Immunol Immunother. 2013;62:1021–8. doi: 10.1007/s00262-013-1418-6. - DOI - PMC - PubMed
    1. Eklund JW, Kuzel TM. A review of recent findings involving interleukin-2-based cancer therapy. Curr Opin Oncol. 2004;16:542–6. doi: 10.1097/01.cco.0000142070.45097.68. - DOI - PubMed
    1. Mekhail T, Wood L, Bukowski R. Interleukin-2 in cancer therapy: uses and optimum management of adverse effects. BioDrugs. 2000;14:299–318. doi: 10.2165/00063030-200014050-00003. - DOI - PubMed

Publication types

MeSH terms